To determine whether BCAS2 may serve as a marker of progression and prognosis of human PCa, we performed IHC (Fig. 5a) to stain BCAS2 and β-catenin, which is a potential downstream target of BCAS2, in tissue microarrays that contained benign prostate hyperplasia and PCa tissues. The gene discussed is BCAS2; the disease is benign prostatic hyperplasia.